Can you take Wegovy (semaglutide) after gastric bypass surgery?

Yes, you can take Wegovy® after gastric bypass surgery. Patients who have had other bariatric surgical procedures including lap-band and gastric sleeve can also take the FDA-approved weight loss medication Wegovy. Wegovy (semaglutide) is in the class of medications called GLP-1 receptor agonists which also includes Saxenda® and Ozempic®. A post-bariatric weight regain study found that this class of medication was more effective for weight loss in patients who have had bariatric surgery than non-GLP-1 receptor agonist medications such as phentermine, Qsymia®, and Contrave®. A different study of patients who have had bariatric surgery in the past and were treated with semaglutide (up to 0.5 mg), demonstrated on average ~10% total body weight loss after 6 months.

Learn more about how Form Health clinicians prescribe Wegovy to help patients achieve their weight loss goals.

Form Health logo
ABOUT THE AUTHOR

Form Health

Form Health is a virtual obesity medicine clinic founded in 2019 that provides science-based obesity care to help patients achieve their weight loss and health goals. Patients have the opportunity to achieve sustainable weight loss by working closely with an American Board of Obesity Medicine physician and a Registered Dietitian who is a Board Certified Specialist in Obesity and Weight Management. Each Care Team develops a personalized treatment plan based on a comprehensive review of their medical history that includes behavioral support, nutrition, physical activity, and medication, if appropriate.

Doctor, healthy food,  man on a computer , and smiling women sitting on counter in baggy yellow sweatshirt

Find your Form

Take the first step to your healthier future.

Get Started
Disclaimer: The content made available on The Form Health Website represents the views and opinions of the authors and not those of other entities, such as the manufacturers of products mentioned therein.  
Wegovy®, Saxenda®, and Ozempic® are registered trademarks of Novo Nordisk A/S. Contrave® is a registered trademark of Currax Pharmaceuticals, LLC. Qsymia® is a registered trademark of VIVUS LLC